Royal Bank of Canada
ELDN icon

Royal Bank of Canada’s Eledon Pharmaceuticals ELDN Stock Holding History

Royal Bank of Canada’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Buy
6,073
+5,073
+507% +$18.4K ﹤0.01% 6221
2026
Q1 		$3K Sell
1,000
-592
-37% -$1.39K ﹤0.01% 6580
2025
Q4 		$3K Sell
1,592
-36,263
-96% -$86.2K ﹤0.01% 6820
2025
Q3 		$98K Sell
37,855
-2,338
-6% -$6.83K ﹤0.01% 5521
2025
Q2 		$109K Buy
+40,193
New +$121K ﹤0.01% 5569
2024
Q3 		– Sell
-40
Closed – – 6999
2024
Q2 		$0 Hold
40
– – ﹤0.01% 7176
2024
Q1 		$0 Sell
40
-68
-63% -$121 ﹤0.01% 7149
2023
Q4 		$0 Sell
108
-158,099
-100% -$220K ﹤0.01% 7236
2023
Q3 		$217K Sell
158,207
-115,138
-42% -$154K ﹤0.01% 4722
2023
Q2 		$374K Buy
+273,345
New +$570K ﹤0.01% 4174
2022
Q4 		– Sell
-38
Closed – – 7338
2022
Q3 		$0 Buy
+38
New +$121 ﹤0.01% 7537
2020
Q4 		– Hold
0
– – – 7113
2020
Q3 		– Sell
-25
Closed -$246 – 6698
2020
Q2 		$0 Buy
25
+11
+79% +$124 ﹤0.01% 6687
2020
Q1 		$0 Buy
+14
New +$134 ﹤0.01% 6745
2019
Q4 		– Sell
-14
Closed – – 6887
2019
Q3 		$0 Buy
+14
New +$201 ﹤0.01% 6793
2019
Q1 		– Sell
-1
Closed – – 6877
2018
Q4 		$0 Hold
1
– – ﹤0.01% 6838
2018
Q3 		$0 Buy
+1
New +$102 ﹤0.01% 6776
2018
Q1 		– Hold
0
– – – 6445
2017
Q4 		– Sell
-22
Closed -$1.66K – 6619
2017
Q3 		$2K Hold
22
– – ﹤0.01% 6556
2017
Q2 		$2K Buy
22
+20
+1,000% +$2.04K ﹤0.01% 6263
2017
Q1 		$0 Hold
2
– – ﹤0.01% 6646
2016
Q4 		$0 Buy
+2
New +$383 ﹤0.01% 6666
2016
Q1 		– Hold
0
– – – 6425
2015
Q4 		– Sell
-2
Closed -$3.48K – 6683
2015
Q3 		$4K Sell
2
-3
-60% -$6.18K ﹤0.01% 6218
2015
Q2 		$10K Buy
+5
New +$9.67K ﹤0.01% 6039

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Royal Bank of Canada's ELDN Position: Q2 2026 in Review

Royal Bank of Canada increased its Eledon Pharmaceuticals (ELDN) stake by 507% in Q2 2026, buying an estimated $18.4K and bringing the position to 6,073 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #6221.

Royal Bank of Canada first reported a position in ELDN in Q2 2015 and has held it in 22 quarters since. The position peaked at $374K in Q2 2023. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Royal Bank of Canada held 6,073 shares of Eledon Pharmaceuticals worth $24K as of Q2 2026.
  • Royal Bank of Canada bought 5,073 Eledon Pharmaceuticals shares in Q2 2026, an estimated $18.4K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6221 holding.
  • Royal Bank of Canada first reported a position in Eledon Pharmaceuticals in Q2 2015 and has held it in 22 quarters since.
  • Royal Bank of Canada's Eledon Pharmaceuticals position peaked at $374K in Q2 2023.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.